'Hanmi Pharm Surpasses Cumulative Sales of 1 Trillion Won... Achieves Record-Breaking Performance'

Hanmi Pharm succeeded in surpassing 1 trillion KRW in cumulative annual sales within just three quarters. This is the first achievement since the founding of Hanmi Pharm. It is also expected to exceed last year's annual sales of 1.3315 trillion KRW.

Exterior view of Hanmi Pharm headquarters building
[Photo by Hanmi Pharm]

Hanmi Pharm announced on the 1st that its consolidated operating (preliminary) results for the third quarter of this year were sales of 364.613 billion KRW and operating profit of 57.518 billion KRW. Compared to the same period last year, sales increased by 6.6% and operating profit by 22.9%.

The cumulative performance up to the third quarter this year showed sales of 1.068537 trillion KRW, an increase of 9.0% compared to the same period last year, successfully surpassing 1 trillion KRW in cumulative sales within three quarters. Cumulative operating profit was 150.591 billion KRW, up 26.3% from last year.

The company explained, "There was steady growth domestically and at Beijing Hanmi," adding, "Operating profit grew, and the operating profit margin also increased."

By major products, the dyslipidemia treatment 'Rosuzet' recorded sales of 45.5 billion KRW in the third quarter, growing 19.8% compared to the same period last year. The hypertension treatment 'Amozalatan Family' achieved 35.2 billion KRW, and the gastroesophageal reflux disease treatment 'Esomazol Family' recorded 15.9 billion KRW, maintaining growth in key products.

Beijing Hanmi posted sales of 93.3 billion KRW in the third quarter, showing a modest growth of 0.3% compared to the same period last year. However, operating profit increased by 7.7% to 26.0 billion KRW. The company stated, "Operating profit increased due to sales growth and efficient cost management."

Hanmi Pharm also reported investing 136.286 billion KRW in research and development (R&D) costs cumulatively this year, which accounts for 12.8% of sales. In the third quarter alone, an investment of 45.1 billion KRW, equivalent to 12.4% of consolidated sales, was made.

Meanwhile, Hanmi Science, the holding company of Hanmi Group, achieved record-high results with preliminary consolidated sales of 309.357 billion KRW and operating profit of 35.751 billion KRW in the third quarter. Sales increased by 22.8% and operating profit by 112.7% compared to the same period last year.

A Hanmi Group official said, “Centered on the group holding company Hanmi Science, the sustainable growth of each business company, including Hanmi Pharm, is becoming more distinct,” adding, “We will do our best to fulfill the role of a technology-driven innovative pharmaceutical and bio company representing Korea through bold investments and innovative R&D for the future.”